In vitro activity of arbekacin against multidrug-resistant gram-negative bacilli.
Clicks: 287
ID: 258236
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
287 views
62 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #3 of 3 articles by views in Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Arbekacin is a broad-spectrum aminoglycoside with activity against some Gram-positive and Gram-negative bacteria.Arbekacin minimum inhibitory concentration (MIC) values were determined for 296 drug-resistant Gram-negative bacilli, and compared to previously determined plazomicin, amikacin, gentamicin, and tobramycin MIC values.The MIC values required to inhibit 50% and 90% of isolates (MIC and MIC, respectively) were 16 and >128 μg/ml, respectively.Arbekacin showed similar MIC values to amikacin and gentamicin, a lower MIC value than tobramycin, and a higher MIC value than plazomicin.
| Reference Key |
albano2020invitrojournal
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Albano, Mariana;Fleischmann, Wim Alexander;Greenwood-Quaintance, Kerryl E;Patel, Robin; |
| Journal | Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi |
| Year | 2020 |
| DOI |
S1684-1182(20)30216-4
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.